330 related articles for article (PubMed ID: 37106400)
1. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy.
Ma GL; Lin WF
Mil Med Res; 2023 Apr; 10(1):20. PubMed ID: 37106400
[TBL] [Abstract][Full Text] [Related]
2. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
Liu Z; Xiang Y; Zheng Y; Kang X
Front Immunol; 2022; 13():1027124. PubMed ID: 36341334
[TBL] [Abstract][Full Text] [Related]
3. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy.
Shim MK; Song SK; Jeon SI; Hwang KY; Kim K
Expert Opin Drug Deliv; 2022 Jun; 19(6):641-652. PubMed ID: 35603410
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
5. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
6. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
7. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
[TBL] [Abstract][Full Text] [Related]
8. Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy.
Zhou H; Yu CY; Wei H
Int J Pharm; 2024 Mar; 652():123818. PubMed ID: 38253269
[TBL] [Abstract][Full Text] [Related]
9. Boosting Checkpoint Immunotherapy with Biomaterials.
Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
[TBL] [Abstract][Full Text] [Related]
10. Role of B cells in immune-related adverse events following checkpoint blockade.
Dhodapkar KM; Duffy A; Dhodapkar MV
Immunol Rev; 2023 Sep; 318(1):89-95. PubMed ID: 37421187
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X
Front Immunol; 2022; 13():915094. PubMed ID: 36189283
[TBL] [Abstract][Full Text] [Related]
12. Boosting Checkpoint Immunotherapy with Biomimetic Nanodrug Delivery Systems.
Chen W; Tang C; Chen G; Li J; Li N; Zhang H; Di L; Wang R
Adv Healthc Mater; 2024 Jun; 13(14):e2304284. PubMed ID: 38319961
[TBL] [Abstract][Full Text] [Related]
13. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
Zhou X; Chen X; Han L; Liu H
Clin Sci (Lond); 2022 May; 136(10):771-785. PubMed ID: 35621125
[TBL] [Abstract][Full Text] [Related]
16. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
17. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
20. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
Lu G; Qiu Y; Su X
Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
